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ABSTRACT
Despite several molecular signatures for “lower grade diffuse gliomas” (LGG) have 
been identified, WHO grade still remains a cornerstone of treatment guidelines. Mitotic 
count bears a crucial role in its definition, although limited by the poor reproducibility 
of standard Hematoxylin & Eosin (H&E) evaluation. Phospho-histone-H3 (PHH3) and 
Ki-67 have been proposed as alternative assays of cellular proliferation. Therefore 
in the present series of 141 LGG, the molecular characterization (namely IDH status, 
1p/19q co-deletion and MGMT promoter methylation) was integrated with the tumor 
“proliferative trait” (conventional H&E or PHH3-guided mitotic count and Ki-67 index) 
in term of prognosis definition. Exclusively high PHH3 and Ki-67 values were predictor 
of poor prognosis (log rank test, P = 0.0281 for PHH3 and P = 0.032 for Ki-67), 
unlike standard mitotic count. Based on Cox proportional hazard regression analyses, 
among all clinical (age), pathological (PHH3 and Ki-67) and molecular variables (IDH, 
1p/19q codeletion and MGMT methylation) with a prognostic relevance at univariate 
survival analysis, only IDH expression (P = 0.001) and Ki-67 proliferation index (P 
= 0.027) proved to be independent prognostic factors. In addition, stratifying by 
IDH expression status, high Ki-67 retained its prognostic relevance uniquely in the 
IDH negative patient (P = 0.029) doubling their risk of death (hazard ratio = 2.27). 
Overall, PHH3 immunostaining is the sole reliable method with a prognostic value 
to highlight mitotic figures in LGG. Ki-67 proliferation index exceeds PHH3 mitotic 
count as a predictor of patient’s prognosis, and should be integrated with molecular 
markers in a comprehensive grading system for LGG. 
INTRODUCTION
Lower-grade diffuse gliomas (LGG) (World 
Health Organization -WHO- grade II and III diffuse 
gliomas) are diffusely infiltrative primary glial brain 
tumors including astrocytomas, oligodendrogliomas, and 
mixed oligoastrocytomas. LGG bear a highly variable 
clinical behavior, as some of them rapidly progress to 
glioblastoma (WHO grade IV gliomas), whereas others 
and have a remarkable therapeutic sensitivity, remaining 
stable for years [1]. Current treatment options are driven 
by the extent of resection, histotype, tumor grade, and the 
results of ancillary testing. Several molecular signatures 
have now been identified (IDH, 1p/19q co-deletion, 
ATRX, TERT, p53, MGMT promoter methylation), 
with important diagnostic, prognostic, and predictive 
roles. This allows further stratification of gliomas into 
several distinct subgroups [2]. Nevertheless, both WHO 
Oncotarget21191www.impactjournals.com/oncotarget
grade and glioma morphology remain two cornerstones 
of treatment guidelines and ongoing clinical trials 
[3, 4]. Glioma grading is based on the definition of 
few morphological features, including mitotic count, 
observation of increased cellularity with nuclear atypia, 
necrosis and microvascular proliferation. The diagnostic 
reproducibility of morphologic criteria for LGG is still 
influeced by a considerable inter-observer variability 
among pathologists [5, 6]. One of the major determinants 
of such variability concerns the proliferative activity, as 
WHO grading criteria does not define strict mitotic figure 
cut-offs to distinguish grade II from grade III tumors. 
Mitotic count is based on the observation of the number 
of mitoses per 10 high power fields (mitoses/10HPF) on 
standard Hematoxylin and Eosin (H&E) stained slides. 
The accuracy of this method can be influenced by both 
technical artifacts and experience of the pathologist 
performing the count. To overcome these inconveniences, 
phospho-histone-H3 (PHH3) and MIB1/Ki-67 have been 
proposed as alternative assays of cellular proliferation. 
PHH3 is a mitosis-specific antibody, which highlights 
the cell nucleus during the late-G2 and all mitotic stages, 
but negligibly at any other time (including apoptosis) 
[7, 8]. Conversely, Ki-67 is the most reliable marker of 
cell proliferation, which stains cells in all phases of cell 
cycle except G0. In LGG, Colman et al. [9] compared 
the prognostic significance of standard H&E-based 
mitotic count (number of mitoses per 10 HPF), PHH3-
based mitotic index (number of mitoses per 1000 cells), 
and Ki-67 proliferation index (number of positive nuclei 
per 1000 cells), identifying prognostic cut-off for each 
method (≤3 versus > 3/10 HPF for H&E, ≤ 4 versus > 4/ 
1000 cells for PHH3 and ≤ 9 versus > 9 for Ki-67) and 
proposing PHH3 as the most useful and clinical relevant 
proliferation marker. The same cut-off for PHH3 was 
recently [2] adopted by the same group to demonstrate a 
PHH3 prognostic role only in specific subsets defined by 
the presence or absence of IDH mutation. 
However, to the best of our knowledge in LGG a) 
the inter-observer reproducibility of PHH3 has never been 
investigated, b) the initially proposed PHH3 thresholds 
[9] were not further validated by other groups, c) an 
exhaustive comparison of proliferation assays as well as 
d) the meaning of their integration with prognostic and 
predictive relevant molecular markers are still lacking. 
Therefore, a comprehensive morphological and 
molecular study on a series of 141 LGG was designed 
to evaluate the reliability of different methods to assess 
proliferation and to define their effect in modulating the 
prognostic role of molecular characterization.
RESULTS
Clinicopathological features
The clinical and pathological features of all cases 
are summarized in Table 1 and Figure 1. There were 83 
males and 58 females, having a median age of 50 Years 
(range 19-81). Most patients received chemotherapy only, 
based on temozolomide, an alkylating agent. The series 
accounted for 67 oligodendrogliomas, 55 astrocytomas, 
and 19 mixed oligo-astrocytomas. According to WHO 
histological grading, 118 cases (84%) were grade II, 
while the remaining 23 (16%) were classified as grade III. 
In the study 81 of 139 cases (58%) were IDH mutated, 
among which the majority were oligodendrogliomas (41, 
29%). Co-deletion of 1p19q was present in 37 of 79 tumor 
tested (47%), 34 of which were IDH mutated. Finally, 
MGMT promoter methylation was a feature of 105 out 
of 139 cases analyzed (75%). A diagram of the complete 
analytical strategy, and the flow of patients through the 
study, including the number of patients included at each 
stage of the analysis, is shown in Figure 2.
Table 1: Clinicopathological features of the whole series.
All patients IDHMutation
1p/19q 
co-deletion
MGMT 
methylation
Age
       
≤40
>40
41
100
34
44
14
23
34
71
Sex femalemale
58
83
36
42
15
22
46
59
Treatment
observation
chemotherapy (TMZ)
RT alone
RT+TMZ
not available
31
57
11
22
20
22
30
8
10
8
8
19
3
1
6
25
43
8
15
14
Histotype
Oligodendroglioma
Astrocytoma
Oligoastrocytoma
67
55
19
41
22
15
29
2
6
50
37
18
WHO grade II 118 62 30 84
III 23 16 7 21
Abbreviations: RT, radiotherapy; TMZ, temozolomide.
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Figure 1: Clinical and molecular data regarding the whole cohort of 141 LGG. Each column represents a patient. In two 
patients with wild type IDH and lacking 1p/19q co-deletion, the tissue was insufficient for IDH direct sequencing.
Figure 2: Diagram illustrating analysis strategy and number of patients included at each step. Given that some samples 
had missing clinical or molecular data, fewer patient samples were available for Cox-Proportional Hazards analysis.
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Correlation and reproducibility of mitotic count 
methods: H&E compared to PHH3
Manually counted mitoses had a median value of 
1 /10 HPF (range 0-8) on H&E-stained slides. All cases 
were evaluable for the PHH3 antibody, which allowed for 
a more straightforward and swift count as highlighted. 
With the PHH3 antibody, the median mitotic count was 
of 2 mitoses/10 HPF (range 0-13). A quasi-Poisson 
regression model for PHH3 versus H&E mitotic counts 
showed a good fit in particular for small counts (Figure 
3A). The fitted model was PHH3 = exp(0.62+0.14xH&E), 
with residual deviance 451.9 (df = 157, dispersion 
parameter = 3.03). After evaluating the same set of slides, 
another observer produced a mean value of 0 (range 
0-9) and 1 (range 0-12) mitoses/10 HPF for H&E-based 
and PHH3 mitotic count, respectively. As for the first 
observer, a quasi-Poisson regression model showed a 
good association for PHH3 versus H&E mitotic counts 
(PHH3 = exp(0.66+0.26xH&E), residual deviance 281.3, 
df = 159, dispersion parameter = 1.61) (Figure 3B). H&E 
mitotic counts were found with a high internal consistency 
between observers (alpha cronbach = 0.82) and the same 
happened for mitotic counts evaluated on PHH3 stained 
slides (alpha cronbach = 0.906). Bland-Altman plots 
demonstrated a high degree of agreement both for H&E 
and for PHH3 mitotic counts (H&E mean difference: 
-0.468, 95% confidence interval = -2.78, 1.84 Figure 3C; 
PHH3 mean difference: -0.68, 95% confidence interval = 
-3.65, 2.28 Figure 3D). 
Comparison between H&E/PHH3 mitotic counts 
and Ki-67 proliferation index
Ki-67 proliferation index had a median value of 6% 
(range 0-30%). The estimated quasi-Poisson regression 
models for H&E and PHH3 and the covariate Ki-67 were, 
respectively, H&E = exp(-0.18+0.07xKi-67) and PHH3 
= exp(0.75+0.07xKi-67). The residual deviances for the 
two fitted models were, respectively, 271.2 (df = 142, 
dispersion parameter = 2.2) (Figure 3E) and 453.05 (df 
= 142, dispersion parameter = 3.68) (Figure 3F). Both 
quasi-Poisson regression models showed a good fit in 
particular for small counts. In both cases, the Spearman’s 
correlations (r = 0.40 and 0.45, for Ki-67 against H&E and 
PHH3, respectively) were lower than that of PHH3 with 
H&E (r = 0.57).
Correlation between clinico-pathological variables 
and proliferation measures
Both mitotic count methods and Ki-67 proliferation 
index were significantly associated with the histological 
diagnosis, having mixed oligo-astrocytic tumors higher 
values compared to oligodendrogliomas and astrocytomas 
(Kruskal-Wallis test, P = 0.002 for H&E, P = 0.005 
for PHH3 and P = 0.039 for Ki-67). The significant 
association between high mitotic count and elevated 
histological grade (grade III) on H&E (Wilcoxon test, 
P= 0.018) was remarkably increased when using PHH3 
(Wilcoxon test, P = 0.0002) and Ki-67 (Wilcoxon test, P < 
0.0001). MGMT promoter methylation was related to high 
mitotic counts and PHH3 values (Wilcoxon test, P = 0.025 
for H&E, P = 0.008 for PHH3, but not with Ki-67 values 
(Wilcoxon test, P = 0.279). Conversely, IDH mutation was 
not found to be associated with mitotic counts (Wilcoxon 
test, P = 0.271 for H&E, P = 0.135 for PHH3) or with 
Ki-67 index (P = 0.782) and the same occurred for 1p/19q 
co-deletion (Wilcoxon test, P = 0.619 for H&E, P = 0.825 
for PHH3 and P = 0.642 for Ki-67).
PHH3 and Ki-67-specific thresholds based on 
overall survival
As expected, at univariate survival analysis, both 
IDH mutation, 1p/19q co-deletion and MGMT methylation 
were all related to an improved survival (univariate Cox 
regression, P < 0.001 for IDH mutated, P = 0.001 for 
1p/19q co-deleted and 0.008 for MGMT methylated cases 
Table 2). With respect to the three methods for assessing 
proliferation, only high PHH3 and Ki-67 values were 
significantly associated with a poor outcome (univariate 
Cox regression, P = 0.0281 for PHH3 and P = 0.032 for 
Ki-67, Table 2). Cut-off points specific for PHH3 and Ki-
67, which divided cases into different groups based on 
their prognosis, were selected on the basis of the highest 
statistical significance on the log-rank test (lowest P 
values). The optimal cut-off was ≤ 6 and ≥ 7 for PHH3, 
and < 8.5% and ≥ 8.5% for Ki-67.
Cox multivariate analysis using a backward stepwise 
selection was performed based on these thresholds and 
on all other parameters with a statistical significance at 
univariate survival analysis. Within a restricted cohort 
(57 cases) for whom all co-variates were available, 
only IDH mutation status and Ki-67 proliferation index 
were statistically significant (Table 2). In addition, the 
Cox model applied to the same subset stratified by IDH 
mutation status showed a significant difference according 
to Ki-67 expression in the IDH wild type group (P = 
0.034), but not in the IDH mutated (P = 0.197). As a 
matter of fact, IDH wild type patients with high Ki-67, 
had a doubled risk of death (hazard ratio = 2.27, 95% 
confidence interval 1.06-4.76) compared to those with low 
Ki-67 (Figure 4). 
DISCUSSION
We here, show that a) H&E and PHH3-guided 
mitotic count have a good intra-observer reliability and 
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Figure 3: Quasi-Poisson regression model for PHH3 versus H&E mitotic counts for Observer 1 [PHH3 = 
exp(0.62+0.14xH&E)] (A) and for Observer 2 [PHH3 = exp(0.66+0.26xH&E)] (B). Bland-Altman plots demonstrating the 
mean difference between mitotic counts produced by two observers (H&E
1
 and PHH3
1 
for Observer 1; H&E
2
 and PHH3
2 
for Observer 2) 
based on H&E (-0.468, 95% confidence interval = -2.78, 1.84) C. and on PHH3 stained slides (0.68, 95% confidence interval = -3.65, 2.28) 
(D). Quasi-Poisson regression model for Ki-67 index versus H&E [E, H&E = exp(-0.18+0.07xKi-67)] and PHH3 mitotic count [F, PHH3 
= exp(0.75+0.07xKi-67)]. 
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Table 2: Univariate analysis for overall survival.
HR 95% CI p-value
Age° 1.03 1.01-1.05 0.004
Histological diagnosis
oligodendrogliomas vs astrocytomas
oligodendrogliomas vs oligoastrocytomas
2.63
2.94
0.79-2.68
0.55-3.79
0.22
0.499
WHO grade (III vs II) 1.11 0.49-2.46 0.806
H&E mitotic count ° 1.10 0.91-1.31 0.331
PHH3 mitotic count ° 1.11 1.01-1.23 0.028
Ki-67 proliferation index ° 1.05 1.01-1.10 0.032
IDH status
(wild type vs mutant) 3.66 2.04-6.66 <0.001
1p/19q co-deletion 
(non co-deleted vs co-deleted) 2.99 1.23-7.14 0.001
MGMT methylation
(non methylated vs methylated) 2.12 1.2-3.77 0.009
Abbreviations: HR, hazard ratio; CI, confidence interval.
°: Quantitative variable
*: significant parameters at multivariate analysis: Ki-67: HR = 2.28 (95% CI 0.44-1.22), P = 0.001; IDH 
status: HR = 4.36 (95% CI 3.32-8.18), P = 0.0001.
Figure 4: Overall survival curves of wild type IDH LGG segregated into two prognostic groups according to Ki-67 
proliferation index.
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inter-observer reproducibility, especially for lower values; 
b) high PHH3 (but not H&E based) mitotic count and Ki-
67 proliferation index are predictors of poor prognosis; c) 
at multivariate survival analysis, only Ki-67 proliferation 
index and IDH status retain independent prognostic value; 
d) high Ki-67 values identify a poor prognosis subset of 
patients within IDH wild type tumors. 
Mitotic count: PHH3 does not increase intra and 
inter-observer agreement
Mitosis recognition is a major factor responsible 
for the poor diagnostic reproducibility within LGG. 
This is due to the ambiguity of current WHO [10] in 
distinguishing grade II from grade III neoplasms (based 
on a “brisk mitotic activity”) and the lack of a definite 
mitotic figures cut-off. In addition, pathologist’s individual 
expertise significantly influences the accuracy of 
diagnosis. Thanks to an immunohistochemical positivity 
matched to consistent morphologic features, PHH3 
expression allows a rapid and selective recognition of all 
mitoses, therefore limiting under- or over-estimation. The 
great value of PHH3 has already been demonstrated in 
several human tumors in which mitotic count is crucial 
for diagnostic and/or prognostic purposes (i.e. melanoma 
[11], breast cancer [12], gastrointestinal stromal tumor 
[13], adrenocortical carcinoma [14] and meningioma 
[15]). In LGG, two previous reports confirmed the 
diagnostic usefulness of PHH3 [9, 16], although they 
did not investigate the concordance among pathologists. 
Therefore, the first aim of this study was to compare H&E 
and PHH3 intra and inter-observer reproducibility. A high 
concordance between morphologically and PHH3-based 
mitotic counts was detected, resulting in a good intra-rater 
reliability, especially for lower values. In addition, both 
H&E and PHH3-based mitotic count proved to have an 
excellent inter-observer agreement. Therefore, although 
PHH3 staining represents a useful tool to simplify mitosis 
screening in LGG, unlike other brain neoplasms, such as 
meningiomas [15], it does not perform any better than 
standard H&E assessment in terms of inter-observer 
reproducibility.
Setting of specific PHH3 and Ki-67 thresholds in 
LGG
A comparison between the prognostic performance 
of mitotic counting (either H&E or PHH3 based) and 
Ki-67 proliferation index proved that exclusively PHH3-
based mitotic count and Ki-67 proliferation index 
were associated to a greater risk of death at univariate 
survival analysis. Therefore, although the reproducibility 
of the two mitotic count methods is comparable, we 
discourage from using standard H&E slides in favor of 
PHH3 immunohistochemistry. For PHH3 mitotic count 
and Ki-67 proliferation index, specific cut-offs based on 
the highest statistical significance (lowest P values) on 
the overall survival were proposed. For LGG, a PHH3-
specific threshold of 4 mitoses per 1000 cells had already 
been proposed [9] and subsequently confirmed [16]. 
However, this cut-off referred to a mitotic index, and not 
to a true mitotic count, which according to the WHO has 
to be performed in 10 consecutive HPF within the area 
of highest mitotic activity. We identified ≤ 6 and ≥ 7 
mitoses/10 HPF as the best cut-off for PHH3 mitotic count. 
With respect to Ki-67, two independent groups introduced 
similar thresholds: 8% for Schiffer et al. [17] and 9% for 
Colman et al. [9]. Accordingly, in the present work we 
identified < 8.5% and ≥ 8.5% as the optimal cut-off with 
the highest statistical performance for Ki-67. Therefore, 
it can reasonably be concluded that the values of Ki-67, 
around 8 and 9%, are those that best discriminate two 
groups associated to a significantly different prognosis.
Prognostic impact of a Ki-67-based stratification 
within the distinct molecular subclasses of LGG
The discovery of the mutations in the IDH1 and 
2 genes and the consistent deletion of chromosomal 
arms 1p and 19q represent to date the major diagnostic 
breakthrough in LGG classification, which bears 
prognostic impact. At this regard, the debate to what 
extent to integrate (or rely on) molecular data has become 
more and more underpinned [18, 19]. The integration 
of genome wide data by various groups has delineated 
different prognostic classes, which were more concordant 
with IDH and 1p/19q statuses than with histologic 
classifications [2]. As a consequence, the third and final 
purpose of this work focused on the use of PHH3 and/or 
Ki-67 as a complementary tool to molecular diagnosis in 
LGG prognostication. Based on Cox proportional hazard 
regression analyses, our data shows that among all clinical 
(age), pathological (PHH3 and Ki-67), and molecular 
variables (IDH, 1p/19q co-deletion and MGMT promoter 
methylation) bearing prognostic impact at univariate 
survival analysis, only IDH mutation and Ki-67 index 
were independent prognostic factors. Therefore, this 
is the first study demonstrating the Ki-67 superiority to 
mitotic count (irrespective of the method of estimation, 
standard H&E or PHH3-guided) in terms of prognostic 
stratification. In addition, after IDH stratification, Ki-
67 retained its prognostic value solely in the IDH wild 
type patients. This finding is consistent with previous 
data [16] reporting that prognostic relevance for PHH3 
mitotic index was limited to the cohort of IDH wild 
type LGG. The latter observation broadens the potential 
tools available to define patients’ risk stratification and is 
strong enough to point towards a molecular-proliferative 
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integrated and comprehensive grading system in LLG. 
MATERIALS AND METHODS
Tissue collection
141 gliomas were retrieved from the pathology files 
of the University of Torino. All patients were resected 
at the Neurosurgery Unit of City of Health and Science 
Hospital of Turin (Molinette) between 2005 and 2014. The 
treatment of patients consisted of maximal safe resection, 
followed by observation or postoperative radiotherapy, 
and/or chemotherapy, depending on the histology, 
grade and extent of resection. For all cases, the clinico-
pathological data were obtained and analyzed. The study 
received ethical approval from the local Review Board of 
our Institution.
Immunohistochemistry, fluorescence in situ 
hybridization and molecular analyses
All available H&E stained slides were reviewed, 
and a representative paraffin block was selected for 
each case. Three μm thick serial paraffin sections were 
processed by immunohistochemistry using an automated 
immunostainer (Ventana BenchMark AutoStainer, Ventana 
Medical Systems, Tucson, AZ, USA) with antibodies 
against PHH3-Ser10 (Cell Marque-Roche, rabbit 
polyclonal antibody, prediluted, 0.03 µg/ml, Rocklin, 
CA, USA), Ki-67 (Dako, mouse monoclonal antibody, 
clone MIB-1, dilution 1/100, Glostrup, Denmark) and 
IDH1 R132H mutation (Dianova, monoclonal antibody, 
clone H09, dilution 1/20, Hamburg, Germany). A biotin-
free, dextran chain-based detection system (EnVysion, 
Dako) and diaminobenzidine as the chromogen (Ventana 
Medical Systems, Tucson, AZ, USA) were used according 
to standard protocols. Appropriate positive controls were 
included. In case of IDH1 negative immunohistochemistry, 
IDH1/IDH2 mutations were further investigated by direct 
sequencing. IDH1 codons 100 and 132 and IDH2 codon 
172 were evaluated according to standardized procedure. 
The tissue of two cases was not sufficient for IDH1/IDH2 
molecular analysis. 1p/19q chromosomal arms co-deletion 
status was assessed by fluorescence in situ hybridization 
(FISH) using probes against 1p36/1q25 and 19q13/19p13 
(Abbott Molecular, North Chicago, IL, USA). Methylation 
MGMT status was assessed by pyrosequencing. The 
extracted DNA was subjected to polymerase chain 
reaction (PCR) amplification with a forward primer and 
a biotinylated reverse primer using the “MGMT plus” 
kit (Diatech Pharmacogenetics, Jesi, Ancona, Italy); 
10 CpG sites in the following regions: chromosome 10: 
131,266,507-131,265,556 were evaluated).
Morphological and PHH3-based mitotic index 
assessment
To assess the reproducibility of the mitotic count 
evaluation, all H&E and PHH3 stained slides were 
evaluated by two pathologists (AP, ED) who were 
separately asked to manually count mitoses in 10 
consecutive HPF (each = x 400), both on H&E and PHH3 
stained sections using the same microscope, with HP field 
set at the dimension of 0.16 mm2. PHH3-labelled mitotic 
figures were considered in the presence of a positive 
staining and consistent morphologic features [20]. The Ki-
67 proliferation index was determined counting 1000 cells 
in hot spots and calculated as the percentage of positive 
nuclei by one senior pathologist (RS).
Statistical analysis
Statistical analyses were performed using the free 
software R (http://www.r-project.org/). A significance 
level of 0.05 was used. Non parametric tests (Wilcoxon-
Mann-Whitney and Kruskal Wallis rank sum) were used 
to analyze differences between different conditions. 
Cronbach’s alpha was used to estimate the reliability of 
H&E and PHH3 mitotic counts. The relationships between 
H&E and PHH3 mitotic counts were studied using 
Poisson-type regression models [21], a class of models 
needed for dealing with possible over-dispersed count 
data. Overall survival was defined as the time elapsed 
from the date of lung cancer diagnosis to the date of death 
or the last visit. Survival analyses were performed using 
Kaplan-Meier estimates of survival distributions and 
survival curves were compared using the log-rank test. 
Cut-off points for H&E and for PHH3, which divided 
cases into prognostically different groups, were selected 
on the basis of the highest statistical significance (lowest 
P value) on the log-rank test among the groups. Finally, 
hazard ratios and 95% confidence intervals were estimated 
by the Cox proportional hazards model for multivariate 
survival analysis.
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